Chinese Journal of Tissue Engineering Research ›› 2021, Vol. 25 ›› Issue (1): 6-12.doi: 10.3969/j.issn.2095-4344.2153

    Next Articles

Umbilical cord mesenchymal stem cell transplantation in the treatment of ischemic heart disease: a 3-year follow-up

Jing Yucheng1 , Wang Le1 , Wang Xianyun2 , Wei Mei1 , Li Min1 , Ji Lishuang1 , Ma Fangfang1 , Liu Gang1 , Zheng Mingqi1
  

  1. 1 Department of Cardiology, 2 Cell Therapy Laboratory, First Hospital of Hebei Medical University, Shijiazhuang 050031, Hebei Province, China
  • Received:2019-12-24 Revised:2019-12-26 Accepted:2020-03-03 Online:2021-01-08 Published:2020-09-18
  • Contact: Liu Gang, MD, Chief physician, Department of Cardiology, First Hospital of Hebei Medical University, Shijiazhuang 050031, Hebei Province, China Zheng Mingqi, MD, Chief physician, Department of Cardiology, First Hospital of Hebei Medical University, Shijiazhuang 050031, Hebei Province, China
  • About author:Jing Yucheng, Physician, Department of Cardiology, First Hospital of Hebei Medical University, Shijiazhuang 050031, Hebei Province, China Wang Le, Master, Associate chief physician, Department of Cardiology, First Hospital of Hebei Medical University, Shijiazhuang 050031, Hebei Province, China Jing Yucheng and Wang Le contributed equally to this paper.
  • Supported by:
    the Science and Technology Plan Project of Hebei Province, No. 18272405D; the Natural Science Youth Fund Project of Hebei Province, No. C2018206037; the Key Science and Technology Support Plan Project of Hebei Province, No. 16277707D; the Science and Techology Plan Project of Hebei Province, No. 19277757D; the Hebei Health Department Project, No. 20180224

PDF

175

Abstract: BACKGROUND: The traditional treatment methods for ischemic heart disease can temporarily relieve pain and improve the quality of life, but cannot restore and regenerate the myocardial tissue. Stem cells have been reported to possess the potential functions of tissue regeneration and multiplex differentiation characteristics which provide a new opportunity for the ischemic heart disease treatment. Because of the unique advantages of umbilical cord mesenchymal stem cells including easy separation, no immune rejection reaction, no ethical dilemmas and remarkable immunomodulatory effect, umbilical cord mesenchymal stem cells have been considered as one of the most ideal candidate seeds for the treatment of ischemic heart disease. 
OBJECTIVE: To investigate the clinical efficacy of umbilical cord mesenchymal stem cells transplantation in patients with ischemic heart disease in 3-year follow-up. 
METHODS: From January 2013 to June 2016, eight patients with coronary heart disease were admitted to the First Hospital of Hebei Medical University and randomly divided into stem cell transplantation group and control group. Four patients in the stem cell transplantation group received conventional treatment and intravenous infusion of umbilical cord mesenchymal stem cells. Four patients in the control group only received conventional treatment. At 3 years after treatment, cardiac function indexes, biochemical indexes and ST segment changes of electrocardiogram lead II were evaluated in two groups. All patients signed the informed consent. The experiment was approved by the Ethics Committee of First Hospital of Hebei Medical University. 
RESULTS AND CONCLUSION: Patients in each group were alive after 3 years. Compared with the control group, left ventricular ejection fraction and left ventricular fraction shortening displayed an increasing trend in the stem cell transplantation group (P > 0.05). The changes of left ventricular ejection fraction and left ventricular fraction shortening indicated an important statistical improvement in the stem cell transplantation group compared with the control group (P < 0.05). There was no significant improvement in New York Heart Association classification between the two groups. The biochemical indicators revealed no significant statistical difference between the two groups (P > 0.05). ST segment changes of different electrocardiogram leads were various before and after treatment in both groups. This study can only show that human umbilical cord mesenchymal stem cells can improve the cardiac function of patients with ischemic heart disease to a certain extent, but there is no significant improvement in the classification of cardiac function, biochemical indicators, and the influence on electrocardiogram leads is not clear. Thus, the significance of this treatment method needs further study. 


Key words: stem cells,  umbilical cord mesenchymal stem cells,  ischemic heart disease,  transplantation,  cardiac function,  heart,  follow-up

CLC Number: